Requirement of methotrexate in combination with anti-tumor necrosis factor-α therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis

Journal of Rheumatology

Volumn 34, Issue 12, 2007, Pages 2326-2333

  Matsuno, Hiroaki ^a   Yoshida, Kaoru ^b   Ochiai, Akira ^b   Okamoto, Masahiro ^c  

^a Matsuno Clinic for Rheumatic Diseases   (Japan)

^b TOIN UNIVERSITY OF YOKOHAMA   (Japan)

^c SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Osteoclastogenesis; Rheumatoid arthritis; SCID mouse; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BONE DESTRUCTION; BONE DISEASE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN-6; METHOTREXATE; MICE; MICE, SCID; OSTEOCLASTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36849039086     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2002;4:226-31.
3. Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 2005;28:239-48.
4. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-9.
5. Chin JE, Winterrowd GE, Krzesicki RF, Sanders ME. Role of cytokines in inflammatory synovitis: coordinate regulation of intercellular adhesion molecule 1 and HLA class I and II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum 1990;33:1776-86.
6. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996;137:4058-60.
7. Jimi E, Akiyama S, Tsurukai K, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
8. Nakagawa N, Kinoshita M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast diffentiation factor in osteoclastogenesis. Biochem Biophys Commun 1998;253:395-400.
9. Hsu H, Lavey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-5.
10. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
11. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
13. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-51.
14. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
15. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
16. St. Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
17. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
18. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
19. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
20. Sakai K, Matsuno H, Morita I, et al. Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. Arthritis Rheum 1998;41:1251-7.
21. Matsuno H, Yudoh K, Nakazawa F, et al. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera. J Rheumatol 2002;29:1609-14.
22. Matsuno H, Sawai T, Nezuka T, et al. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. Arthritis Rheum 1998;41:2014-21.
23. Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology Oxford 2002;41:329-37.
24. Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
25. Ogawa Y, Otsuki M, Uzuki M, et al. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003;48:3350-8.
26. Bosma GC, Fried M, Custer RP, Carroll A, Gibson DM, Bosma MJ. Evidence of functional lymphocytes in some (leaky) SCID mice. J Exp Med 1988;167:1016-33.
27. Koizumi F, Matsuno H, Wakaki K, Ishii Y, Kurashige Y, Nakamura H. Synovitis in rheumatoid arthritis: Scoring of characteristic histopathological features. Pathol Int 1999;49:298-304.
28. Rooney M, Condell D, Quinlan W, et al. Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 1988;31:956-63.
29. Van der Heijde DM, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
30. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin I. J Exp Med 1986;163:1363-75.
31. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-alpha antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6:225-30.
32. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991;21:2575-9.
33. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1-beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
34. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
35. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003;321:1-15.
36. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. RANK signaling is not required for TNF-alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNF-alpha-mediated inflammatory arthritis. J Bone Miner Res 2004;19:207-13.
37. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005;202:589-95.
38. Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor B, osteoprotegerin, and receptor activator of nuclear factor kB ligand. Arthritis Rheum 2004;50:3831-43.
39. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5′-aminoimidazole- 4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5′-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
40. Cronstein BN. The mechanism of action of methotrexate [review]. Rheum Dis Clin North Am 1997;23:739-55.
41. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
42. Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
43. Gadangi P, Longaker M, Naime D, et al. The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996;156:1937-41.
44. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology Oxford 2003;42:6-13.
45. Larsen A, Kvien TK, Schattenkirchner M, et al; European Leflunomide Study Group. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001;30:135-42.
46. Ichikawa Y, Saito T, Yamanaka H, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005;15:323-8.